Acquisition by Nathaniel Gardiner of 5187 shares of Enanta Pharmaceuticals at 8.99 subject to Rule 16b-3

ENTA Stock  USD 8.60  0.23  2.60%   
About 68% of Enanta Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Enanta Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Enanta Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Enanta Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Enanta Pharmaceuticals Officer: Chief Legal Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Acquisition of 5187 common stock at 8.99 of Enanta Pharmaceuticals by Nathaniel Gardiner on 26th of February 2024. This event was filed by Enanta Pharmaceuticals with SEC on 2024-02-26. Statement of changes in beneficial ownership - SEC Form 4. Nathaniel Gardiner currently serves as senior vice president general counsel of Enanta Pharmaceuticals

Cash Flow Correlation

Enanta Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Enanta Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Enanta Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Enanta Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Enanta Pharmaceuticals Fundamental Analysis

We analyze Enanta Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enanta Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enanta Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Enanta Pharmaceuticals is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Enanta Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Enanta Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Enanta Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enanta Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Enanta Pharmaceuticals Related Equities

GLUEMonte Rosa   13.72   
0%
100.0%
CCCCC4 Therapeutics   8.59   
0%
62.0%
IPSCCentury Therapeutics   5.52   
0%
40.0%
LYELLyell Immunopharma   3.26   
0%
23.0%
CGEMCullinan Oncology   2.75   
0%
20.0%
EWTXEdgewise Therapeutics   2.48   
0%
18.0%
IKNAIkena Oncology   2.37   
0%
17.0%
STOKStoke Therapeutics   1.68   
0%
12.0%
HOWLWerewolf Therapeutics   1.52   
0%
11.0%
DSGNDesign Therapeutics   0.50   
0%
3.0%
MRUSMerus BV   0.29   
2.0%
0%
CRNXCrinetics Pharmaceuticals   0.81   
5.0%
0%
KRONKronos Bio   1.04   
7.0%
0%
RVMDRevolution Medicines   1.25   
9.0%
0%
INBXInhibrx   2.37   
17.0%
0%
MLYSMineralys Therapeutics,   2.59   
18.0%
0%

Complementary Tools for Enanta Stock analysis

When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios